BACKGROUND Paliperidone palmitate is a once-monthly injectable,atypical antipsychotic.To our knowledge,there has been only one report of paliperidone palmitate-induced angioedema presenting with acute laryngeal edema ...BACKGROUND Paliperidone palmitate is a once-monthly injectable,atypical antipsychotic.To our knowledge,there has been only one report of paliperidone palmitate-induced angioedema presenting with acute laryngeal edema with subsequent respiratory arrest.Here,we present a case report of paliperidone palmitate-induced angioedema with a relatively mild clinical presentation compared with the previously reported case,and the patient's condition was not complicated by lifethreatening anaphylaxis.CASE SUMMARY A 79-year-old female,who had a major neurocognitive disorder due to Alzheimer's disease with behavioral disturbances.Paliperidone palmitate was offlabel used to control her aggression,irritability,and psychosis.After induction doses(150 mg and 100 mg intramuscularly,given 1 wk apart),she developed intermittent swelling of the face,eyelids,and lips on day 17 after the initial dose,and the edema was explicitly seen on day 20.The diagnosis was paliperidone palmitate-induced angioedema.The monthly injection dose was discontinued on day 33 after the initial dose.The angioedema was subsequently alleviated,and it had completely resolved by day 40 after the initial dose.CONCLUSION Paliperidone palmitate-induced angioedema is a rare condition and can present with a mild,intermittent facial edema,which may be overlooked in clinical practice.展开更多
Objective To explore the influence of demographic characteristics,psychiatric symptoms and medication on the adherence of long-acting injectable paliperidone palmitate(PP)treatment in schizophrenia patients.Methods In...Objective To explore the influence of demographic characteristics,psychiatric symptoms and medication on the adherence of long-acting injectable paliperidone palmitate(PP)treatment in schizophrenia patients.Methods In this one year,naturalistic longitudinal study,156 consecutive patients with schizophrenia were initi-展开更多
目的系统评价棕榈酸帕利哌酮注射液与其他抗精神病药长效针剂比较治疗精神分裂症的有效性和安全性。方法计算机检索PubMed、Embase、Web of Science、Cochrane Library、PsycINFO、CNKI、SinoMed、VIP、WanFang Data数据库,搜集关于棕...目的系统评价棕榈酸帕利哌酮注射液与其他抗精神病药长效针剂比较治疗精神分裂症的有效性和安全性。方法计算机检索PubMed、Embase、Web of Science、Cochrane Library、PsycINFO、CNKI、SinoMed、VIP、WanFang Data数据库,搜集关于棕榈酸帕利哌酮注射液对比其他抗精神病药长效针剂治疗精神分裂症的随机对照试验(RCT),检索时限均从建库至2023年4月30日。由2名研究者独立筛选、提取资料并评价纳入研究的偏倚风险后,采用RevMan 5.4软件进行Meta分析。结果共纳入12个RCT,包括4368例患者。Meta分析结果显示,棕榈酸帕利哌酮注射液组与利培酮长效针剂组的临床有效率差异无统计学意义(P>0.05),与其他抗精神病药长效针剂组的阳性和阴性症状量表(PANSS)总体评分改变值差异也无统计学意义(P>0.05)。与其他抗精神病药长效针剂组相比,棕榈酸帕利哌酮注射液组总退出率[RR=1.14,95%CI(1.06,1.24),P<0.01]和肌注部位异常的不良反应发生率[RR=2.08,95%CI(1.03,4.22),P=0.04]均显著增加。结论当前证据表明,与其他抗精神病药长效针剂相比,棕榈酸帕利哌酮注射液治疗精神分裂症的有效性并无明显差异,但部分不良反应发生率稍有增加。受纳入研究数量和质量的限制,上述结论尚待更多高质量研究予以验证。展开更多
目的制备棕榈酸帕利哌酮注射液,建立该注射液释放度的检测方法,并进行方法学验证。方法湿磨法制备本品,采用高效液相色谱法建立释放度检测方法并进行方法学验证。结果自制制剂的平均粒径约为1μm,透射电镜下观察为不规则块状;所建立的...目的制备棕榈酸帕利哌酮注射液,建立该注射液释放度的检测方法,并进行方法学验证。方法湿磨法制备本品,采用高效液相色谱法建立释放度检测方法并进行方法学验证。结果自制制剂的平均粒径约为1μm,透射电镜下观察为不规则块状;所建立的释放度检测方法的精密度为1.5%,回收率为100.70%,稳定性RSD为0.33%。3批自制制剂的体外平均释放分别为:1.5 min 8.00%、20 min 62.26%、45 min 85.44%。结论所制备缓释注射液的粒度分布和释放度与原研制剂一致,释放度检查法简单、灵敏、准确,可有效监控本品的质量,3批制剂平均释放度均在质量标准范围之内。展开更多
文摘BACKGROUND Paliperidone palmitate is a once-monthly injectable,atypical antipsychotic.To our knowledge,there has been only one report of paliperidone palmitate-induced angioedema presenting with acute laryngeal edema with subsequent respiratory arrest.Here,we present a case report of paliperidone palmitate-induced angioedema with a relatively mild clinical presentation compared with the previously reported case,and the patient's condition was not complicated by lifethreatening anaphylaxis.CASE SUMMARY A 79-year-old female,who had a major neurocognitive disorder due to Alzheimer's disease with behavioral disturbances.Paliperidone palmitate was offlabel used to control her aggression,irritability,and psychosis.After induction doses(150 mg and 100 mg intramuscularly,given 1 wk apart),she developed intermittent swelling of the face,eyelids,and lips on day 17 after the initial dose,and the edema was explicitly seen on day 20.The diagnosis was paliperidone palmitate-induced angioedema.The monthly injection dose was discontinued on day 33 after the initial dose.The angioedema was subsequently alleviated,and it had completely resolved by day 40 after the initial dose.CONCLUSION Paliperidone palmitate-induced angioedema is a rare condition and can present with a mild,intermittent facial edema,which may be overlooked in clinical practice.
文摘Objective To explore the influence of demographic characteristics,psychiatric symptoms and medication on the adherence of long-acting injectable paliperidone palmitate(PP)treatment in schizophrenia patients.Methods In this one year,naturalistic longitudinal study,156 consecutive patients with schizophrenia were initi-
文摘目的制备棕榈酸帕利哌酮注射液,建立该注射液释放度的检测方法,并进行方法学验证。方法湿磨法制备本品,采用高效液相色谱法建立释放度检测方法并进行方法学验证。结果自制制剂的平均粒径约为1μm,透射电镜下观察为不规则块状;所建立的释放度检测方法的精密度为1.5%,回收率为100.70%,稳定性RSD为0.33%。3批自制制剂的体外平均释放分别为:1.5 min 8.00%、20 min 62.26%、45 min 85.44%。结论所制备缓释注射液的粒度分布和释放度与原研制剂一致,释放度检查法简单、灵敏、准确,可有效监控本品的质量,3批制剂平均释放度均在质量标准范围之内。
